Skip to main content

Hereditary Angioedema News

Research Review
03/18/2026
Jessica Garlewicz
Results of an analysis highlight the importance of integrating multisystem evaluation into the long-term care of HAE-C1INH patients, and stress the need for early and accurate diagnosis to prevent mismanagement and unnecessary procedures.
Results of an analysis highlight the importance of integrating multisystem evaluation into the long-term care of HAE-C1INH patients, and stress the need for early and accurate diagnosis to prevent mismanagement and unnecessary procedures.
Results of an analysis highlight...
03/18/2026
Allergy & Immunology
Research Review
03/18/2026
Rebecca Mashaw
All participants reported at least one negative impact on HRQoL due to injectable on-demand treatment.
All participants reported at least one negative impact on HRQoL due to injectable on-demand treatment.
All participants reported at...
03/18/2026
Allergy & Immunology
Research Review
03/18/2026
Jessica Garlewicz
This analysis highlights the emergence of oral agents as a practical alternative to parenteral therapies for both prophylaxis and acute attack management
This analysis highlights the emergence of oral agents as a practical alternative to parenteral therapies for both prophylaxis and acute attack management
This analysis highlights the...
03/18/2026
Allergy & Immunology
Research Highlights
03/18/2026
Jessica Garlewicz
The results of a physician survey highlight ongoing barriers to implementing consensus recommendations and underscore the need for broader education and improved access to therapy for HAE.
The results of a physician survey highlight ongoing barriers to implementing consensus recommendations and underscore the need for broader education and improved access to therapy for HAE.
The results of a physician...
03/18/2026
Allergy & Immunology
Emerging Therapies
03/02/2026
Jessica Garlewicz
The future of HAE management will likely focus on tailoring regimens to patient-specific needs, attack phenotypes, and treatment goals.
The future of HAE management will likely focus on tailoring regimens to patient-specific needs, attack phenotypes, and treatment goals.
The future of HAE management...
03/02/2026
Allergy & Immunology
Research Summary
01/18/2026
Rebecca Mashaw
New survey data highlight persistent disease burden, frequent attacks, and widespread concern about lifelong medication use among patients being treated for hereditary angioedema.
New survey data highlight persistent disease burden, frequent attacks, and widespread concern about lifelong medication use among patients being treated for hereditary angioedema.
New survey data highlight...
01/18/2026
Allergy & Immunology
Research Highlights
01/16/2026
Rebecca Mashaw
The 2025 global consensus represents a major step forward in unifying global expert opinion on HAE-nC1INH diagnosis and care.
The 2025 global consensus represents a major step forward in unifying global expert opinion on HAE-nC1INH diagnosis and care.
The 2025 global consensus...
01/16/2026
Allergy & Immunology
Research Highlights
12/06/2025
Jessica Garlewicz
Study findings underscore the need for heightened clinical surveillance and early recognition to avoid unnecessary procedures and improve long-term patient outcomes.
Study findings underscore the need for heightened clinical surveillance and early recognition to avoid unnecessary procedures and improve long-term patient outcomes.
Study findings underscore the...
12/06/2025
Allergy & Immunology
Patient-Reported Outcomes
12/06/2025
Jessica Garlewicz
This analysis highlights the persistent challenges that impact health-related quality of life (HRQoL) across emotional, social, and practical domains.
This analysis highlights the persistent challenges that impact health-related quality of life (HRQoL) across emotional, social, and practical domains.
This analysis highlights the...
12/06/2025
Allergy & Immunology
Clinical Trials
11/13/2025
Jessica Garlewicz
Interim results from the open-label extension of the CHAPTER-1 phase 2 trial support the long-term efficacy and safety of deucrictibant, an oral bradykinin B2 receptor antagonist, for hereditary angioedema prophylaxis
Interim results from the open-label extension of the CHAPTER-1 phase 2 trial support the long-term efficacy and safety of deucrictibant, an oral bradykinin B2 receptor antagonist, for hereditary angioedema prophylaxis
Interim results from the...
11/13/2025
Allergy & Immunology